N-<4-(10,11-dihydro-5H-dibenzoazepin-5-yl)butyl>-N,N-dimethylamine | 2064-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: N-<4-(10,11-dihydro-5H-dibenzoazepin-5-yl)butyl>-N,N-dimethylamine
• 英文别名: [4-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-butyl]-dimethyl-amine；5-(4-dimethylamino-butyl)-10,11-dihydro-5H-dibenz[b,f]azepine；5-(4-Dimethylamino-butyl)-10,11-dihydro-5H-dibenz[b,f]azepin；10,11-dihydro-5-[4-(dimethyl amino)-butyl]-5H-dibenz(b,f)azepine；5-<4-Dimethylamino-butyl>-iminodibenzyl；4-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylbutan-1-amine
• CAS: 2064-12-2
• 化学式: C₂₀H₂₆N₂
• 分子量: 294.44
• InChiKey: LNFGXLOAHGOSNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  亚氨基二苄 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 氢气 作用下， 120.0 ℃ 、11.0 MPa 条件下， 反应 48.0h， 生成 N-<4-(10,11-dihydro-5H-dibenzoazepin-5-yl)butyl>-N,N-dimethylamine
  参考文献：
  名称：

  通过铑催化杂环烯丙基胺的羰基化氢氨基甲基化一锅合成药理活性二胺

  摘要：

  吩噻嗪，亚氨基二苄基，咔唑和吡唑的药理活性衍生物是通过使相应的N-烯丙基或N-甲基烯丙基化合物，伯或仲胺，一氧化碳和氢在[Rh（cod）Cl通过一锅加氢甲酰化-胺缩合-还原顺序得到作为催化剂的] 2。图选项

  DOI：

  10.1016/s0040-4020(99)00536-0

文献信息

• Design, Synthesis, and Evaluation of New Chemosensitizers in Multi-Drug-Resistant <i>Plasmodium </i><i>f</i><i>alciparum</i>
  作者：Jian Guan、Dennis E. Kyle、Lucia Gerena、Quan Zhang、Wilbur K. Milhous、Ai J. Lin

  DOI：10.1021/jm010549o

  日期：2002.6.1

  A series of new chemosensitizers (modulators) against chloroquine-resistant Plasmodium falciparum were designed and synthesized in an attempt to fabricate modulators with enhancing drug-resistant reversing efficacy and minimal side effects. Four aromatic amine ring systems-phenothiazine, iminodibenzyl, iminostilbene, and diphenylamine-were examined. Various tertiary amino groups including either noncyclic or cyclic aliphatic amines were introduced to explore the steric tolerance at the end of the side chain. The new compounds showed better drug-resistant reversing activity in chloroquine-resistant than in mefloquine-resistant cell lines and were generally more effective against chloroquine-resistant P. falciparum isolates from Southeast Asian (W2 and TM91C235) than those from South America (PC49 and RCS). Structure-activity relationship studies revealed that elongation of the alkyl side chain of the molecule retained the chemosensitizing activity, and analogues with four-carbon side chains showed superior activity. Furthermore, new modulators with phenothiazine ring exhibited the best chemosensitizing activity among the four different ring systems examined. Terminal amino function has limited steric tolerance as evidenced by the dramatic lose of the modulating activity, when the size of substituent at the amino group increases. The best new modulator synthesized in this study possesses all three optimized structural features, which consist of a phenothiazine ring and a pyrrolidinyl group joined by a four-carbon alkyl bridge. The fractional inhibitory concentration TIC) index of the best compound is 0.21, which is superior to that of verapamil (0.51), one of the best-known multi-drug-resistant reversing agents. Some of the analogues displayed moderate intrinsic in vitro antimalarial activity against a W-2 clone of P. falciparum.
• DE829167
  申请人：——

  公开号：——

  公开（公告）日：——
• CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS
  申请人：Abrams Daniel J.

  公开号：US20090069267A1

  公开（公告）日：2009-03-12

  The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
• US4249002A
  申请人：——

  公开号：US4249002A

  公开（公告）日：1981-02-03
• US4249003A
  申请人：——

  公开号：US4249003A

  公开（公告）日：1981-02-03